87929-30-4

Upstream product

• 57625-74-8 methyl 2-methyl-2-phenylpropionate 
• 756-79-6 dimethyl methane phosphonate 

Downstream Products

• 635310-12-2 methyl 4-{2-(2R)-2-[(1E)-4-methyl-3-oxo-4-phenylpent-1-enyl]-5-oxopyrrolidin-1-yl} ethyl benzoate 
• 540731-23-5 7-[(R)-2-((E)-4-Methyl-3-oxo-4-phenyl-pent-1-enyl)-5-oxo-pyrrolidin-1-yl]-heptanoic acid ethyl ester 

Relevant academic research and scientific papers

GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF

1,2-substituted 5-pyrrolidinone compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, sleep disorder, or gastric ulcer, inflammatory disorders and other diseases and disorders associated with the prostaglandin family of compounds.

2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives

Disclosed herein are novel prostaglandin I2 (PGI2) derivatives exhibiting excellent in vivo duration and activities, said derivatives being represented by the general formula: STR1 wherein R1, X, R2 and R3 are as defined herein.